Alopecia areata: A condition caused by an overactive immune system attacking hair follicles.There is a genetic component to this condition, but more research is needed. Androgenetic alopecia (male ...

But living with alopecia areata doesn’t mean you have to accept facial hair loss if you’re not comfortable with it. Several cosmetic procedures are available to help address AA and conceal the ...

The study saw 158 participants with mild or moderate alopecia areata receive one of four doses of STS-01—ranging from 0.25% to 2%—or placebo applied over 24 weeks.

Equillium announced positive topline data from its phase 2, single-dose, proof-of-concept study of EQ101 for the treatment of adults with moderate, severe or very severe alopecia areata, according ...

A medicine for severe hair loss, or alopecia, is being recommended on the NHS for the first time. The daily pill, called ritlecitinib or Litfulo, could help up to 14,000 people in England, says ...

Concert Pharmaceuticals managed to keep hold of the breakthrough tag for its alopecia areata therapy, even though the approval of Eli Lilly’s rival gave the FDA second thoughts.. Concert secured ...

A new treatment for severe alopecia got the Food and Drug Administration’s stamp of approval on June 23. The drug, which is called Litfulo (with the generic name ritlecitinib), is the first and ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...

On the heels of Eli Lilly’s landmark approval last summer, Pfizer is stepping up to the plate in alopecia areata—and it’s coming equipped with an adolescent nod to put the pressure on Olumiant.

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire Tue, Dec 10, 2024, 4:05 PM 11 min read ...